Breaking News Instant updates and real-time market news.

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$309.38

0.44 (0.14%)

14:03
11/13/19
11/13
14:03
11/13/19
14:03

U.S., China trade talks hit snag over farm purchases, WSJ reports

Trade talks between the U.S. and China have hit a snag over farm purchases, Wall Street Journal reports, citing according to people familiar with the matter. While President Trump has said China has agreed to buy up to $50B in U.S. soybeans, pork and other agricultural products annually, China is leery of putting a numerical commitment in the text of a potential agreement, sources tell the Journal. China wants to avoid reaching a deal that looks one-sided in Washington's favor, and also wants to have a way out should trade tensions escalate again, the sources added. Publicly traded companies in the agriculture space include Agrium (AGU), Andersons (ANDE), Archer Daniels (ADM), Bunge (BG), CF Industries (CF), Compass Minerals (CMP), Intrepid Potash (IPI), Potash (POT) and Syngenta (SYT). Reference Link

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$309.38

0.44 (0.14%)

ADM

Archer Daniels

$42.85

-0.4 (-0.92%)

AGU

Agrium

$0.00

(0.00%)

CF

CF Industries

$46.61

-1.28 (-2.67%)

POT

Potash

$0.00

(0.00%)

ANDE

Andersons

$22.85

-0.36 (-1.55%)

SYT

Syngenta

$0.00

(0.00%)

BG

Bunge

$54.77

-0.99 (-1.78%)

IPI

Intrepid Potash

$2.24

-0.105 (-4.48%)

CMP

Compass Minerals

$55.53

-1.3 (-2.29%)

  • 13

    Nov

  • 13

    Nov

  • 19

    Nov

SPX S&P 500
$0.00

(0.00%)

09/30/19
JPMS
09/30/19
NO CHANGE
JPMS
JPMorgan upgrades Eurozone equities to Overweight, downgrades U.S.
JPMorgan equity strategist Mislav Matejka, who has held a longstanding preference for the U.S. over Eurozone equities, now believes that there is a "tactical opportunity opening up for Eurozone to catch up." As such, he upgraded Eurozone to Overweight, funding from the U.S., which leads to a downgrade of U.S. to Neutral. The Eurozone is sitting on a "significant spell of underperformance and it is underowned," Matejka tells investors in a research note. With a "valuation discount," any increase in fiscal stimulus speculations could be a help for the sentiment of European stocks, contends the analyst.
12/06/18
DBAB
12/06/18
NO CHANGE
DBAB
Deutsche lowers probability of U.S., China trade deal after Huawei CFO arrest
Following reports that the CFO of Huawei was detained in Canada on December 1 due to an U.S. extradition request over Iran sanctions, Deutsche Bank analyst Zhiwei Zhang lowered his probability of the U.S. and China reaching a trade deal by March 1 to 30% from 40%. The arrest is a "clear signal that the trade war is escalating to a new level," Zhang tells investors in a research note partially titled "Huawei case is a big deal." U.S. business interests in China "face higher risk than before," says the analyst. He points out that Huawei has been widely recognized as one of the most successful technology companies in China.
07/15/19
JPMS
07/15/19
NO CHANGE
JPMS
JPMorgan boosts S&P 500 12-month price target to 3,200
JPMorgan strategist Dubravko Lakos-Bujas boosted his S&P 500 12-month price target to 3,200 saying his "upside case for equities is increasingly in play." The Federal Reserve and Trump administration are easing on policy while investor positioning and sentiment remains low, Lakos-Bujas tells investors in a note to investors.
SPY SPDR S&P 500 ETF Trust
$309.38

0.44 (0.14%)

ADM Archer Daniels
$42.85

-0.4 (-0.92%)

10/07/19
SPHN
10/07/19
INITIATION
Target $50
SPHN
Overweight
Stephens starts Archer Daniels at Overweight with $50 price target
As previously reported, Stephens analyst Ben Bienvenu initiated coverage of Archer Daniels with an Overweight rating and $50 price target. Fundamentals have been under pressure due to investments in future growth and current uncertainty in the global trade environment, but he thinks patient, value-oriented investors have a solid entry point at current levels into a company paying a healthy dividend while new businesses mature and the company's "more normalized" earnings power returns.
10/07/19
SPHN
10/07/19
INITIATION
Target $50
SPHN
Overweight
Archer Daniels initiated with an Overweight rating at Stephens
Stephens analyst Ben Bienvenu initiated coverage of Archer Daniels with an Overweight rating and $50 price target.
08/26/19
BARD
08/26/19
NO CHANGE
BARD
Outperform
Archer Daniels weakness a buying opportunity, says Baird
Baird analyst Ben Kallo said the recent weakness in Archer Daniels has created a compelling entry point. The analyst said significant macro headwinds have been priced in and he think s the Readiness Initiatives and historical investments in Nutrition may be underappreciated. Kallo reiterated his Outperform rating and $48 price target on Archer Daniels shares.
07/12/19
BARD
07/12/19
NO CHANGE
BARD
Outperform
Darling Ingredients named a Fresh Pick at Baird
Baird analyst Ben Kallo named Darling Ingredients (DAR) as a Fresh Pick as he believes a rally in fat pricing should be a tailwind for the balance of the year. While he is more positive on Darling (DAR), Kallo said weather, trade, and African swine fever combine to make challenging ag environment more broadly and he is cautious in the near-term on Archer Daniels (ADM), Bunge (BG) and FMC Corporation (FMC). He keeps Outperform ratings on Darling and Archer and Neutral ratings on Bunge and FMC.
AGU Agrium
$0.00

(0.00%)

CF CF Industries
$46.61

-1.28 (-2.67%)

09/23/19
CEDG
09/23/19
INITIATION
Target $70
CEDG
Overweight
CF Industries initiated with an Overweight at Consumer Edge
Consumer Edge initiated CF Industries with an Overweight and $70 price target.
10/31/19
SBSH
10/31/19
NO CHANGE
Target $103
SBSH
Buy
Citi names FMC top pick in Ag, boosts target to $103 from $98
Citi analyst P.J. Juvekar raised his price target for FMC Corporation (FMC) to $103 from $98 saying the company reported "an all-round robust quarter," with growth across most geographies and segments. FMC is now the analyst's top pick in Agriculture, followed by Nutrien (NTR) then CF Industries (CF). He keeps a Buy rating on FMC. Ag chemicals is a better market than fertilizers, which tend to be commoditized, Juvekar tells investors in a research note.
10/25/19
CLVD
10/25/19
NO CHANGE
CLVD
CF Industries, Mosaic estimates lowered at Cleveland Research
Cleveland Research analyst Mike Piken lowered his FY19 estimates for both CF Industries (CF) and Mosaic (MOS) to reflect the fact that phosphate market conditions have continued deteriorating and he sees increased odds of an average to worse fall fertilizer application season in the U.S. Piken has Neutral ratings on both stocks.
09/26/19
COWN
09/26/19
NO CHANGE
Target $62
COWN
Outperform
CF Industries remains a top pick in the Ag space, says Cowen
Cowen analyst Charles Neivert said CF Industries remains his favorite name in the Ag space after meeting with management. The meeting highlighted its operational and industry fundamentals but management believes the corn crop estimate are still too high and nitrogen inventories are balanced. Neivert raised his estimates for 2019 and his price target to $62 from $59 while reiterating his Outperform rating on CF Industries shares.
POT Potash
$0.00

(0.00%)

ANDE Andersons
$22.85

-0.36 (-1.55%)

10/07/19
10/07/19
INITIATION

Equal Weight
Andersons initiated with an Equal Weight at Stephens
As previously reported, Stephens analyst Ben Bienvenu initiated coverage of Andersons with an Equal Weight rating and $21 price target. The analyst said that despite the "suppresed valuation and solid leadership" at the company, he remains cautious due to challenging fundamentals, lack of visibility, and earnings that he sees remaining under pressure.
10/07/19
SPHN
10/07/19
INITIATION
Target $21
SPHN
Equal Weight
Andersons initiated with an Equal Weight rating at Stephens
Stephens analyst Ben Bienvenu initiated coverage of Andersons with an Equal Weight rating and $21 price target.
06/06/19
BUCK
06/06/19
NO CHANGE
Target $30
BUCK
Neutral
Andersons price target loweed to $30 from $39 at Buckingham
Buckingham analyst Eric Larson maintained a Neutral rating on Andersons but lowered his price target to $30 from $39, saying he expects improving Grain fundamentals, year one accretion from the Lansing acquisition and a stable outlook for Rail to be "materially" offset by a challenging environment for Plant Nutrient and Ethanol.
SYT Syngenta
$0.00

(0.00%)

BG Bunge
$54.77

-0.99 (-1.78%)

02/22/19
BMOC
02/22/19
NO CHANGE
Target $72
BMOC
Outperform
Bunge price target lowered to $72 from $83 at BMO Capital
BMO Capital analyst Kenneth Zaslow lowered his price target on Bunge to $72 after its Q4 earnings miss driven by a higher tax rate and expectations of flat FY19 EPS because of lower Agribusiness profits. The analyst also keeps his Outperform rating, saying investment in the stock may be "ripe" because of the appointment of new management, "severe earnings rebase", potential asset sales, cost savings opportunities, and limited downside given its current price relative to $48-$49 per share book value.
01/23/19
FBCO
01/23/19
NO CHANGE
Target $70
FBCO
Outperform
Bunge price target lowered to $70 from $77 at Credit Suisse
Credit Suisse analyst Robert Moskow lowered his price target for Bunge to $70 from $77 following management's EBIT guidance reduction for its Agribusiness and Sugar segment. The analyst reiterates an Outperform rating on the shares due to his view that Bunge's newly constituted board will generate shareholder value by slimming down the portfolio, improving execution, and possibly selling the business.
10/08/19
SPHN
10/08/19
INITIATION
Target $74
SPHN
Overweight
Bunge initiated with an Overweight rating at Stephens
Stephens analyst Ben Bienvenu initiated coverage of Bunge with an Overweight rating and $74 price target. He thinks shares are at an attractive entry point for long-term investors with near-term downside protection and a favorable dividend. Bienvenu also sees potential for new management to unlock the earnings power of "a business that has been consistently under-earning," the analyst stated.
IPI Intrepid Potash
$2.24

-0.105 (-4.48%)

03/25/19
COWN
03/25/19
NO CHANGE
COWN
Plantings report likely to create volatility for fertilizer stocks, says Cowen
Cowen analyst Charles Neivert said the annual Prospective Plantings report, due out on Friday, March 29 at noon, is likely to create some volatility around fertilizer shares as it represents the first important data point for the upcoming U.S. agricultural season. Grower economics favor corn over soybean acres as of now, said Neivert, who noted that expectations are for corn and wheat acres to rise, soybean acres to decline, and cotton acres to remain about flat. Agricultural chemicals stocks covered by the firm included CF Industries (CF), Nutrien (NTR), Intrepid Potash (IPI), CVR Partners (UAN) and Mosaic (MOS).
CMP Compass Minerals
$55.53

-1.3 (-2.29%)

11/27/18
FBCO
11/27/18
UPGRADE
FBCO
Neutral
Compass Minerals upgraded to Neutral from Underperform at Credit Suisse
11/07/19
BMOC
11/07/19
NO CHANGE
Target $55
BMOC
Market Perform
Compass Minerals price target lowered to $55 from $60 at BMO Capital
BMO Capital analyst Joel Jackson lowered his price target on Compass Minerals to $55 and kept his Market Perform rating after its Q3 earnings miss and a cut in FY19 adjusted EBITDA outlook. The analyst is also cutting his FY19 and FY20 EPS views by 15c and 49c to $2.18 and $3.25 to reflect the weaker South American ag/chemicals earnings and lower North American volumes, with slightly higher costs in Salt.
11/27/18
11/27/18
UPGRADE
Target $49

Neutral
Compass Minerals upgraded to Neutral on symmetric risk/reward at Credit Suisse
As previously reported, Credit Suisse analyst Christopher Parkinson upgraded Compass Minerals to Neutral from Underperform, with $49 price target. While the analyst is not more positive on its story, the -29% move since February reflects investors' frustration with its inability to execute in the Salt segment. Parkinson still sees risks to 2019 estimates, but views management changes, a likely renegotiation with creditors and the snowfall season as balancing risk/reward.

TODAY'S FREE FLY STORIES

PLMR

Palomar

20:27
12/08/19
12/08
20:27
12/08/19
20:27
Recommendations
Palomar analyst commentary  »

Palomar price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

ASAZY

Assa Abloy

$0.00

(0.00%)

20:23
12/08/19
12/08
20:23
12/08/19
20:23
Downgrade
Assa Abloy rating change  »

Assa Abloy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RXEEY

Rexel

$0.00

(0.00%)

20:23
12/08/19
12/08
20:23
12/08/19
20:23
Upgrade
Rexel rating change  »

Rexel upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TATYY

Tate & Lyle

$0.00

(0.00%)

20:22
12/08/19
12/08
20:22
12/08/19
20:22
Upgrade
Tate & Lyle rating change  »

Tate & Lyle upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUO

AU Optronics

$0.00

(0.00%)

20:20
12/08/19
12/08
20:20
12/08/19
20:20
Upgrade
AU Optronics rating change  »

AU Optronics upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPL

LG Display

$6.22

0.115 (1.89%)

20:17
12/08/19
12/08
20:17
12/08/19
20:17
Upgrade
LG Display rating change  »

LG Display upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

ETNB

89bio

$28.38

0.86 (3.13%)

20:16
12/08/19
12/08
20:16
12/08/19
20:16
Initiation
89bio initiated  »

89bio initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANIOY

Acerinox

$0.00

(0.00%)

20:15
12/08/19
12/08
20:15
12/08/19
20:15
Upgrade
Acerinox rating change  »

Acerinox upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

20:15
12/08/19
12/08
20:15
12/08/19
20:15
Conference/Events
Blueprint Medicines to hold an anlayst and investor event »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

TLSNY

Telia

$0.00

(0.00%)

20:14
12/08/19
12/08
20:14
12/08/19
20:14
Downgrade
Telia rating change  »

Telia downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARWR

Arrowhead

$67.25

1.705 (2.60%)

20:13
12/08/19
12/08
20:13
12/08/19
20:13
Recommendations
Arrowhead analyst commentary  »

Arrowhead price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARGX

Argenx

$147.31

-2.56 (-1.71%)

20:08
12/08/19
12/08
20:08
12/08/19
20:08
Recommendations
Argenx analyst commentary  »

Argenx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

STC

Stewart

$43.16

0.28 (0.65%)

19:56
12/08/19
12/08
19:56
12/08/19
19:56
Downgrade
Stewart rating change  »

Stewart downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FAF

First American

$63.05

(0.00%)

19:55
12/08/19
12/08
19:55
12/08/19
19:55
Downgrade
First American rating change  »

First American downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

PFSI

PennyMac Financial

$33.91

0.12 (0.36%)

19:54
12/08/19
12/08
19:54
12/08/19
19:54
Downgrade
PennyMac Financial rating change  »

PennyMac downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

18:40
12/08/19
12/08
18:40
12/08/19
18:40
Recommendations
Agios Pharmaceuticals analyst commentary at Piper Jaffray »

Agios' initial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

18:34
12/08/19
12/08
18:34
12/08/19
18:34
Recommendations
Blueprint Medicines analyst commentary at Piper Jaffray »

Piper says 'jury…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

18:29
12/08/19
12/08
18:29
12/08/19
18:29
Recommendations
Fate Therapeutics analyst commentary at Piper Jaffray »

FT500 data validates Fate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCKT

Rocket Pharmaceuticals

$22.37

2.61 (13.21%)

18:05
12/08/19
12/08
18:05
12/08/19
18:05
Hot Stocks
Rocket says Phase 1 trial establishes feasibility of commercial Process B for FA »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

ARGX

Argenx

$147.31

-2.56 (-1.71%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

18:03
12/08/19
12/08
18:03
12/08/19
18:03
Recommendations
Argenx, Johnson & Johnson analyst commentary at Piper Jaffray »

Argenx data on…

ARGX

Argenx

$147.31

-2.56 (-1.71%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 16

    Dec

  • 21

    Jan

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

17:58
12/08/19
12/08
17:58
12/08/19
17:58
Recommendations
Bluebird Bio, Johnson & Johnson, Amgen, Bristol-Myers, Regeneron analyst commentary at Piper Jaffray »

Piper says…

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

AMGN

Amgen

$233.74

0.3 (0.13%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

REGN

Regeneron

$372.26

4.02 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

  • 21

    Jan

BGNE

BeiGene

$186.89

-2.3 (-1.22%)

17:50
12/08/19
12/08
17:50
12/08/19
17:50
Hot Stocks
BeiGene announces data from two clinical trials of Brukinsa at ASH meeting »

BeiGene announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 27

    Feb

LLY

Eli Lilly

$119.59

-0.175 (-0.15%)

16:34
12/08/19
12/08
16:34
12/08/19
16:34
Hot Stocks
Eli Lilly presents interim clinical data from LOXO-305 dose escalation trial »

Eli Lilly announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 17

    Dec

  • 30

    Jan

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

16:32
12/08/19
12/08
16:32
12/08/19
16:32
Hot Stocks
Bristol-Myers announces data from multiple liso-cel studies at ASH meeting »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

QURE

uniQure

$66.06

1.5 (2.32%)

16:26
12/08/19
12/08
16:26
12/08/19
16:26
Hot Stocks
uniQure reports 1-year follow-up data from etranacogene dezaparvovec study »

uniQure announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.